Medivir AB (FRA:MVR0)
€ 0.229 0.007 (3.15%) Market Cap: 27.89 Mil Enterprise Value: 14.38 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 53/100

Q2 2024 Medivir AB Earnings Call Transcript

Aug 22, 2024 / 12:00PM GMT
Release Date Price: €0.247 (-3.14%)
Jens Lindberg
Medivir AB - Chief Executive Officer

Thank you very much and a warm welcome, everyone to the quarter two results webcast here at Medivir. I hope everyone has had a great summer as we sort of kick off again, after a warm and long summer vacation.

Here at Medivir of you, we closed out quarter two sort of at the beginning of the summer on a very high note when we presented sort of a strong data set for the first structure, Lenvima combination at ESMO GI Congress in Munich, and we will come back to that and share a bit more details today in terms of the data presented. And how we are now working forward with the Fostrox development program.

So important information which you will find as you access the presentation on the website. As mentioned in quarter two we were able to share a very exciting data set at ESMO GI, where we can see or could see for the Fostrox Lenvima combination, a superior efficacy compared with what has been shown in previous published studies in the second-line liver cancer space.

Equally important, we could confirm in that data set, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot